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Abstract
Objectives. The aim of this study was to develop a
Turkish version of the painDETECT questionnaire
(PD-Q) and assess its reliability and validity.
Methods. Two hundred and forty patients who were
diagnosed by expert pain physicians in daily clinical
practice and classified as having either neuropathic,
nociceptive, or mixed pain for at least 3 months were
enrolled in this study. After the usual translation
process, the Turkish version of the PD-Q was admin-
istered to each participant twice with an interval
of 48 hours. The Leeds Assessment of Neuropathic
Symptoms and Signs (LANSS), Douleur Neuro-
pathique en 4 questions (DN4) and a pain visual
analog scale were assessed along with the PD-Q.
Chronbach’s α was calculated to evaluate internal
consistency of the PD-Q. Intraclass correlation coef-
ficient was calculated to examine test-retest reliabil-
ity. Convergent validity was assessed by correlating
the scale with LANSS and DN4. Discriminant
statistics—sensitivity, specificity, Youden index,
positive predictive value, negative predictive
value—were also assessed.
Results. A total of 240 patients with chronic pain, 80
patients in each neuropathic, nociceptive, and
mixed pain group, were included in this study. Mean
age of the patients was 54.1 years, and majority of
the patients were female (52.9%). Chronbach’s α of
the Turkish version of the PD-Q was 0.81. The test-
retest reliability of the Turkish version of the PD-Q
was determined as 0.98 for the total score and
ranged from 0.86 to 0.99 for individual items. The
Turkish version of the PD-Q was possitively and
significantly corralated with LANSS (r 0.89,
P < 0.001) and DN4 (r 0.82, P < 0.001). When the two
cutoff values in the original version were used, sen-
sitivity was found 77.5% for a cutoff value ≤19, and
specificity was 82.5%. Sensitivity and specificity
were 90% and 67.5%, respectively, for the other
cutoff value ≤12. Scores ≤12 represents a negative
predictive value = 87%, and scores 19≤ represents a
positive predictive value = 82%. When mixed pain
patients were included in the neuropathic pain
group, discriminant values were reduced as
expected.
Conclusions. The Turkish version of the PD-Q is a
reliable and valid scale to be used to determine neu-
ropathic component of chronic pain in Turkish
patients.
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Introduction
Management of patients presenting with chronic pain is a
common problem in medical care. The accurate assess-
ment of pain type in chronic pain patients is important to
improve the therapeutic outcome. Chronic pain can be
classified as three main categories: nociceptive pain, neu-
ropathic pain, and mixed pain as the coexistence of noci-
ceptive and neuropathic pain [1,2]. Because nociceptive
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and neuropathic components require different pain man-
agement strategies, certain diagnosis of pain type is
required [2].
The International Association for Study of Pain defined
neuropathic pain recently as “pain caused by a lesion or
disease of the somatosensory system” [3]. There are no
accurate data for the overall prevalence of neuropathic
pain, but it is considered that chronic neuropathic pain is
underrecognized and undertreated [4]. Neuropathic pain
is not a single disease, but a syndrome caused by a range
of different diseases and lesions, which has a consider-
able impact on the quality of life [2,5]. Despite being
related to various type of nerve lesions, neuropathic pain
syndromes share similar clinical symptoms and signs that
are the result of particular mechanisms and require spe-
cific management [6]. Neuropathic pain screening tools
have gained increasing acceptance in the medical com-
munity. There are several instruments that allow to screen
neuropathic pain components of patients with chronic
pain. The purpose of these diagnostic tools is to help the
clinician to identify patients with neuropathic pain, but they
are not intended to replace clinical examination and clini-
cal judgement [7]. Clinical examination, including accurate
sensory examination, is the basis of neuropathic pain
diagnosis [8].
Various screening tools and questionnaires have been
developed in different countries for detecting neuropathic
pain component of patients with chronic pain based on
verbal pain description, with or without physical examina-
tion [9–15]. The use of these tools in different languages
and cultures could contribute to increase the recognition
of neuropathic pain. Although some of these instruments
are available in Turkish, the painDETECT questionnaire
(PD-Q) validation process in Turkish population has not
been done [16–18]. The PD-Q was developed and vali-
dated to detect neuropathic pain components especially
in chronic low back pain patients in Germany. It is also
available in several other languages [19,20]. The PD-Q is a
reliable screening tool with high sensitivity, specificity, and
positive predictive accuracy [15,19]. The PD-Q is a simple,
self-administered, useful screening questionnaire that was
designed to screen for neuropathic signs and symptoms
without physical examination [15].
Although these tools are based on descriptors, their lin-
guistic adaptation and validation into different languages is
feasible and ensures their reliability and validity in lan-
guages other than those in which they were initially devel-
oped [21]. The aim of this study was to validate the PD-Q
into Turkish and to check its psychometric properties in
the Turkish population.
Materials and Methods
The study protocol was approved by the Institutional
Review Board of the University (registration number:
B.30.2.PAU.0.20.05.09/66, date of approval; March 6,
2012) and each patient provided written informed consent
to participate this study. Patients with each sex, aged 18
years or over, able to speak, and understand Turkish
language, of whom diagnosis of pain type was concurred
by two pain specialists and had chronic pain for at least 3
months with pain visual analog scale (VAS) score three or
more, were included in this study. Pain intensity was evalu-
ated by a 10 cm VAS, asking for the pain experienced
during the last week. Exclusion criteria were: painful syn-
dromes of unknown origin or associated with diffuse pains
(e.g., fibromyalgia), being illiterate, having altered mental
status; being in an analgesic situation and not referring
pain due to pharmacological or nonpharmacological treat-
ments. This study was carried out in the University Faculty
of Medicine, pain management units of Physical Medicine
and Rehabilitation and Neurology Departments between
April and August 2012.
After demographic information was obtained, detailed
medical history and physical examination including
anthropometric measures for determination of body mass
index were performed. Patients were diagnosed by two
expert pain physicians in daily clinical practice and classi-
fied as having either neuropathic, nociceptive, or mixed
pain. Differential diagnosis of patients was based on
medical history, detailed clinical examinations, and appro-
priate diagnostic techniques including neuroimaging and
electrophysiological studies when indicated. The diagno-
sis of neuropathic pain made by two expert pain physi-
cians was considered as the gold standard. Each patient
was examined by two experienced pain specialists
working independently of each other. Patient was included
in the validation study only if the two specialists concurred
in the diagnosis of pain type. Then the patients were
evaluated by another investigator who was blinded to the
pain classification to apply Turkish version of the PD-Q
along with Leeds Assessment of Neuropathic Symptoms
and Signs (LANSS) and Douleur Neuropathique en 4
Questions (DN4). The Turkish version of the PD-Q was
administered to the same patients twice, 2 days apart, by
the same investigator. The result of the experts physicians
was then compared with results of the PD-Q.
Description of the PD-Q
The PD-Q is simple, self-administered, useful screening
questionnaires that allow to detect neuropathic pain com-
ponents in patients with chronic pain. The PD-Q was
developed in Germany in individuals with chronic low back
pain. The PD-Q consists of four main sections. The first
section contains three items with 11-point Likert scale
format with anchor terms in the scale ends (0 = no pain,
10 = maximum pain), accompanied by a color grading
scale representing pain intensity in analog format. These
items assess intensity of pain at the moment, the average
and the maximum pain intensity during the past 4 weeks.
The first section used to diagnose the presence of pain but
not included in the questionnaire scoring. In the second
section, patients were asked to mark one of the four graphs
that best describe their pain course patterns. The possible
patterns and their scores are determined as follows: per-
sistent pain with slight fluctuations (0 points), persistent
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between them (1 point), and pain attacks with pain
between them (1 point). The third section includes a
sensory map representing homunculus along with ques-
tions asking to mark the pain zone, a dichotomous item
about the presence of radiating pain and showing the
direction of radiating pain with an arrow. The positive
answer about the presence of radiating pain is scored with
two points. In the last section, there are seven Likert type
items asking about the intensity of the sensation marked
over the homunculus. These items are scored with a
6-point Likert format, with corresponding ordinal anchor
terms (0 = never, 1 = hardly noticed, 2 = slightly, 3 = mod-
erately, 4 = strongly, 5 = very strongly). These Likert-type
items ask about the following sensations: burning, tingling
or prickling, allodynia, pain attacks, temperature evoked
pain, numbness, and pressure-evoked pain. This last
section provides scores between 0 and 35 points. The final
score is obtained summing up the scores of the last three
sections with a total score of −1 to 38. Two cutoff values are
used by developer of PD-Q for the presense of neuropathic
pain. Scores ≤12 state that a neuropathic pain component
is unlikely, and scores ≤19 indicate that neuropathic com-
ponent is very likely to be present. Scores between 12 and
19 suggest that the result is unclear [15].
LANSS
LANSS is based on analysis of sensory description and
bedside examination of sensory dysfunction. LANSS con-
tains five symptom and two clinical examination items.
The first part consist five dichotomous items asking the
patient about the kind of pain experienced in the last
week. In the second part, presence of allodynia and
altered pinprick perception threshold are explored by
health care professional. Each item should be marked as
present or absent, and the presence of each sign has
different score. The possible scores range from 0 to 24,
with a score of 12 or greater considered to be suggestive
of neuropathic pain [9].
DN4
DN4 is a clinician-administered questionnaire contains
seven items related to symptoms and three related to
clinical examination. A score of 1 is given to each positive
item and a score of 0 to each negative item. The total score
is calculated as the sum of the 10 items, and a total score
of 4 or more out of 10 suggests neuropathic pain [12].
Pain VAS
Pain intensity was evaluated by a 10 cm VAS asking for
the pain experienced during the last week (0, no pain; 10,
worst possible pain).
Linguistic Adaptation
Translation and cross-cultural adaptation of the PD-Q into
Turkish was carried out after the usual process for the
adaptation and validation of patient-reported question-
naires [22,23]. The adaptation procedure was supervised
by an expert committee including experts in pain medicine
and expert in methodology and validation of instruments.
In the first phase, the English version of the PD-Q that was
developed in Germany was translated into Turkish by two
independent translators who were a native Turkish
speaker fluent in English. Both forward translators were
discussed the forward translations item by item that was
highly concordant. After discrepancies had been dis-
cussed, the translation is combined into a new version
with the assistance of an expert committee. The com-
pleted new Turkish version was evaluated for cultural
appropriateness in Turkish patients with chronic pain to
assess initial feasibility and potential understanding prob-
lems. In the back-translation phase, the final Turkish
version of the PD-Q was translated back into English by
two independent English native speaker who were blinded
to the original scale, not have medical background, and
not informed about the concept of PD-Q. Both back
translators were discussed item by item to test concor-
dance with the original instrument. The original question-
naire and the forward and back translations were
discussed by all translators. The differences between
translated versions were evaluated, and a satisfactory
compliance with the original scale was achieved by
consensus of the translators and expert committee. The
translation and back-translation phase of the PD-Q
produced Turkish version of the questionnaire (see
Supplemental at link http://www.pau.edu.tr/tipftr/tr/sayfa/
pain-detect-turkce-versiyonu).
Psychometric Validation
During the first examination, participants were interviewed
to gather information about sociodemographic character-
istics, and the PD-Q was administered to patients, along
with the LANSS scale (administered by the clinician), DN4,
and the pain VAS. All subjects were re-evaluted 48 hours
later. In the second examination, the PD-Q was adminis-
tered again to assess time stability of measurements. The
assessment of the psychometric properties of the PD-Q
focused on reliability and validity with methodological
methods, as described in Spanish validation study [19].
Feasibility was assessed with difficulties found by patients
when answering items, and the number of items not
answered by patients.
Sample size was calculated assuming that at least 240
patients were needed to validate a scale, 80 in each group
(nociceptive, mixed, and neuropathic). A sample size of 73
produces two-sided 95% confidence interval with a dis-
tance from the mean to the limits that is equal to 1.4, with
an estimated standard deviation of 6.0 for Pain Detect
score. Assuming a 10% data loss or unevaluable
questionnaries, the final sample size should be
240 patients.
Statistics
All statistical analyses were performed using SPSS version
15.0 for Windows (Statistical Package for Social Sciences
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descripe demographic characteristics. For continuous
variables, the significance of the differences was analysed
using the one-way analysis of variance (ANOVA) and Stu-
dent’s t-test, while categorical variables was analyzed with
chi-squared test. For reliability analysis, Cronbach’s α was
used to assess the scale internal consistency, and
intraclass correlation coefficient between test and retest
scores was used to assess stability over time. Convergent
validity was assessed by examining correlation between
PD-Q with LANSS and DN4 scores. To evaluate the dis-
criminant validity, patients with nociceptive and neuro-
pathic pain were compared in all scale items and in the
PD-Q overall score (one-way ANOVA, post-hoc Tukey
honestly significant difference, Student’s t, chi-squared
test); Post-hoc Tukey test was performed to correct for
the effect of multiple comparisons when the difference
was detected between the groups. PD-Q sensitivity and
specificity indexes were computed using it for diagnostic
classification of patients compared with clinical judge-
ment. For each total PD-Q score, sensitivity and specificity
were computed and graphed in a receiver operating char-
acteristic (ROC) curve. The ROC curved was used to
select optimal cutoff PD-Q scores for screening patients
who present a neuropathic pain component. The
Youden’s index, positive predictive value, negative predic-
tive value, and positive and negative likelihood ratio were
also obtained. In all analyses, P values <0.05 were con-
sidered as statistically significant.
Results
A total of 258 patients were eligible for this study, 18 of
whom had to be excluded from the analysis. Therefore,
240 patients with chronic pain; 80 patients in each
neuropathic, nociceptive and mixed pain group, were
included in this study. A total of 18 patients were excluded
from the study; 11 of them had pain medication, four had
pain lower than 3 on VAS scale, and three were unable to
understand and answer the questionnaire. The mean age
of the patients was 54.1 years, and the majority of the
patients were female (52.9%). Neuropathic pain patients
had higher mean age and duration of pain than the mixed
and also nociceptive pain group (P < 0.05). There were no
difference in sociodemographical characteristics by main
diagnosed pain type except age and duration of pain as
shown in Table 1 (P > 0.05). Patients in each pain group
Table 1 Demographic characteristics by main diagnosed pain type
Nociceptive (N = 80) Mixed (N = 80) Neuropathic (N = 80) P
Gender, N (%) 0.626
Women 43 (53.8%) 39 (48.8%) 45 (56.2%)
Men 37 (46.2%) 41 (51.2%) 35 (43.8%)





Duration of pain (month)
(mean ± SD)





BMI (kg/m2) (mean ± SD) 27.71 ± 4.18 28.39 ± 4.14 28.56 ± 4.37 0.412
Educational level, N (%) 0.109
Primary 46 (57.5%) 49 (61.2%) 61 (76,3%)
High 20 (25%) 19 (23.8%) 13 (16.2%)
University 14 (17.5%) 12 (15%) 6 (7.5%)
Occupation, N (%) 0.226
Government official 7 (8,8%) 8 (10%) 6 (7.5%)
Employee 16 (20%) 22 (27.5%) 23 (28.8%)
Retired 28 (35%) 21 (26.2%) 14 (17.5%)
Home-maker 28 (35%) 27 (33,8%) 36 (45%)
Student 0 (0%) 2 (2.5%) 0 (0%)
Unemployed 1 (1.2%) 0 (0%) 1 (1.2%)
Marital status, N (%) 0.399
Married 71 (88.8%) 72 (90%) 70 (87.5%)
Single 7 (8.8%) 6 (7.5%) 4 (5%)
Widow(er) 2 (2.5%) 2 (2.5%) 6 (7.5%)
BMI = body mass index; Mix = mixed pain group; Neu = neuropathic pain group; Nos = nociceptive pain group; p* = post-hoc Tukey
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did not differ according to sex, occupation, educational
level, or marital status. This enabled us to interpret that
there was no difference in level of understanding of the
questionnaires in each group.
The majority of patients in neuropathic pain group were
diagnosed as diabetic neuropathy (47.5%), followed by
painful polyneuropathy (25%), central neuropathic pain
(20%), and post-herpetic neuralgia (7.5%). In the mixed
pain group, the more frequent etiology was radiculopathy
(37.5%). Other etiologies were peripheral entrapment
syndrome (32.5%), pain related to oncological disease
(11.2%), mechanical low back pain (11.2%), and complex
regional pain syndrome (7.6%) in the mixed pain group.
The prevalent diagnosis included in nociceptive pain
group were osteoarthritis (37.5%), and the other diagnosis
were myofascial pain syndrome (21.3%), impingement
syndrome (18.8%), epicondylitis/bursitis (13.7%), and
mechanical low back pain (8.7%), respectively.
All PD-Q items, except pain course patterns and radiating
pain, were answered by all patients, showing that they
were well understood. Five patients did not mark any pain
course patterns: two of them in nociceptive, two of them
in neuropathic, and one in mixed pain group. All these
patients stated that none of the available graphs describe
their pain course patterns. All of them had mentioned
persistent pain in the same intensity with no fluctuations or
attacks. Only one patient forgot to fill the radiating pain
item whom pain was nociceptive. Multiple choice were not
observed for any item. The distribution of responses for
the seven Likert-type items did not have ceiling or floor
effect as shown in Table 2. Items 3 and 5 accumulated
more than 30% of responses in the lower category
suggesting a possible floor effect. On the other hand,
when only responses of the neuropathic pain group were
considered, the percentage of responses in the low cat-
egory did not reach 9%. The most frequently selected pain
pattern was pain attacks with pain between them (33.3%)
in the whole sample, and the presence of radiating pain
were reported by 30% of all patients. There were
no statistically significant difference in distribution of
responses for pain course paterns and radiating pain
between pain group.
The mean overall score of PD-Q score was significantly
higher in the neuropathic pain group than both nocicep-
tive and mixed pain group (P < 0.001). The mixed pain
group attained a mean overall score in between the
other two groups, which was significantly lower than the
neuropathic pain group and higher than nociceptive pain
group (P < 0.05). Mean scores of the maximum and the
average pain intensity experienced during the past 4
weeks were higher in the neuropathic pain group than
both nociceptive and mixed pain group; however, the
mean pain intensity in the moment of examination did
not differ significantly between groups (Table 3). Mean
Likert-type item scores were significantly different for the
neuropathic, nociceptive, and mixed pain groups
(P < 0.001). Mean score for each individual item was
always higher in the neuropathic pain group than in the
nociceptive group, supporting the discriminative capabil-
ity of the individual items.
Mean score for the LANSS scale and also DN4 were
significantly higher in the neuropathic pain group than both
nociceptive and mixed pain group; also, mixed pain group
was presented statistically significantly higher mean
Table 2 Frequency distribution of response categories in patients with chronic pain
No
Hardly
Noticed Slightly Moderately Strongly
Very
Strongly
N (%) N (%) N (%) N (%) N (%) N (%)
Burning sensation 58 (24.2) 27 (11.3) 31 (12.9) 52 (21.7) 43 (17.9) 29 (12.1)
Tingling or prickling 46 (19.2) 34 (14.2) 35 (14.6) 55 (22.9) 49 (20.4) 21 (8.8)
Painful light touching 88 (36.7) 28 (11.7) 43 (17.9) 34 (14.2) 27 (11.3) 20 (8.3)
Sudden pain attacks 51 (21.3) 40 (16.7) 42 (17.5) 52 (21.7) 38 (15.8) 17 (7.1)
Temperature evoked pain 75 (31.3) 29 (12.1) 41 (17.1) 47 (19.6) 32 (13.3) 16 (6.7)
Numbness sensation 57 (23.8) 9 (3.8) 35 (14.6) 57 (23.8) 56 (23.3) 26 (10.8)
Pressure evoked pain 56 (23.3) 29 (12.1) 39 (16.3) 44 (18.3) 43 (17.9) 29 (12.1)
Pain course pattern
Persistent pain with slight fluctuations 47 (19.6)
Persistent pain with pain attacks 51 (21.3)
Pain attacks without pain between them 57 (23.8)
Pain attacks with pain between them 80 (33.3)
Missing responses (not answered) 5 (2.1)
Does the pain radiate to other regions of your body?
Yes 72 (30)
No 167 (69.7)











niversity user on 29 January 2021
scores than the nociceptive group (P < 0.001) (Table 3). In
the neuropathic pain group, 81.2% of patients scored 12
or above, which is the cutoff value in LANSS, in compari-
son with 65% in the mixed pain group and 11.2% in the
nociceptive pain group. Furthermore, 96.2% of the
patients in the neuropathic pain group scored 4 or above
from DN4 in comparison with 82.2% in the mixed pain
group and 18.8% in the nociceptive pain group. Pearson
correlation between the LANSS scale and PD-Q scores
was high and statistically significant (r 0.89, P < 0.001).
Also, there was a positive and statistically significant cor-
relation between PD-Q and DN4 (r 0.82, P < 0.001).
Internal consistency for the whole Turkish version of the
PD-Q scale was 0.81 assessed by Cronbach’s α;
however, when only the Likert items were considered,
Cronbach’s α was slightly reduced to 0.80. The mean
overall score of the PD-Q was 16.33 ± 8.35 at baseline
and 15.9 ± 8.17 at the retest measurement. The test-
retest reliability of the Turkish version of the PD-Q was
determined as 0.98 for the total score and ranged from
0.86–0.99 for individual items.
Using the agreement between PD-Q scores and clinical
diagnosis as the gold standard, ROC curve for PD-Q
scores was estimated (Figure 1). Area under the ROC
curve was 0.89 when comparing neuropathic and noci-
ceptive groups. Discriminant statistics—sensitivity, speci-
ficity, Youden index, positive predictive value, negative
predictive value for each possible PD-Q cutoff score—
were given in Table 4 considering neuropathic and noci-
ceptive pain groups only. In this study, when the two cutoff
values in the original version was used sensitivity was
found 77.5% for a cutoff value ≤19 and specificity was









(Mean ± SD) P
Post-hoc
Tukey p*
Pain VAS 6.35 ± 1.93 6.28 ± 1.79 6.66 ± 1.63 0.363 NA






Pain intensity now 6.25 ± 2.17 6.31 ± 1.93 6.74 ± 1.88 0.246 NA
Pain intensity average 6.58 ± 1.87 6.96 ± 1.81 7.57 ± 1.47 0.002 Neu > Nos
p* = 0.001
























DN4 = Douleur Neuropathique en 4 Questions; LANSS = Leeds Assessment of Neuropathic Symptoms and Signs; Mix = mixed pain
group; NA = not applicable; Neu = neuropathic pain group; Nos = nociceptive pain group; p* = post-hoc Tukey honestly significant
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82.5%. Sensitivity and specificity were 90% and 67.5%,
respectively, for the other cutoff value ≤12. If we select
only a single cutoff value, we could use the score ≤17
where sensitivity (81.3%) and specificity (80%) were simul-
taneously maximized with a higher value for the Youden
index = 0.613. Scores ≤12 represents a negative predic-
tive value = 87%, and scores ≤19 represents a positive
predictive value = 82% (Table 4). When mixed pain
patients were included in the neuropathic pain group and
considered as a part of the patients with a neuropathic
pain component, area under the ROC curve was slightly
reduced to 0.86. On the other hand, when patients with
mixed pain were included in the discriminant analysis,
sensitivity was reduced to 70.6% and 84.4% for the origi-
nal cutoff values 19 and 12, respectively, as shown in
Table 5. When mixed pain patients were included in the
neuropathic pain group, discriminant values are reduced
as expected (Table 5). Therefore, a single cutoff value of
≤14 would be better when mixed pain patients were
included in the neuropathic pain group with a higher sen-
sitivity = 79.4% and specificity = 75%.
Discussion
The original version of the PD-Q that was designed to
detect neuropathic pain components in patients with low
back pain has been validated in about 8,000 patients with
low back pain and reaches about 80% sensitivity and
specificity [15]. The original authors suggested two cutoff
points ≤12 with a negative predictive value 85% and ≤19
with a positive predictive value 90%. In the Spanish
version of the PD-Q sensitivity, specificity and the positive
predictive value were 75%, 84%, and 92%, respectively,
when the suggested cutoff value for neuropathic pain
presence of 19 points or higher was used. On the other
hand, when cutoff value of 12 points or below taken into
consideration, sensitivity, specificity, and negative predic-
tive value were 93%, 68%, and 80%, respectively [19].
Discriminant analysis of the Turkish PD-Q was also good,
and the results of sensitivity, specificity, and positive and
negative predictive value were consistent with these
studies. On the other hand, when patients with mixed pain
were included in the analysis, discriminative capability of
PD-Q was reduced.
Turkish version of the PD-Q shows good psychometric
properties in patients with chronic pain. The test-retest
reliability of the Turkish version of the PD-Q seemed to be
good. Stability over time was not assessed by the original
developers [15]; however, in the Spanish validation study,
intraclass correlation coefficient attained a value of 0.93,
which is similar to our findings [19]. Moreover, internal
consistency assessed by Cronbach’s α attained a value of
0.81 for the Turkish version of the PD-Q scale that was
considered good and also consistent with the results of
the original scale [15]. Unlike to these studies, Cronbach’s
α attained a value of 0.86 that increased to 0.89 when
only the Likert items were considered for the Spanish
PD-Q [19].
Comparing PD-Q contents with that of LANNS, DN4, and
6-item identification pain questionnaire scales, the con-
cepts assessed were similar, although the response
method greatly varied [15]. However, in PD-Q, pain course
ROC CurveA B ROC Curve
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Figure 1 (A) Receiver operating characteristic curve for neuropathic pain presence. Area under the curve:
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patterns and radiating pain, which particularly are impor-
tant for back pain, are used through diagnostic items
being different from other tools. Nevertheless, the item
corresponding to radiating pain did not discriminate
between pain groups in the Spanish validation study [19].
In accordance with this finding, we also found no differ-
ence between pain groups according to radiating pain.
This may be because only patients with chronic back pain
were included in the original study, whereas we enrolled all
kinds of neuropathic pain groups similar to Spanish vali-
dation study. Moreover, the rates of responses for pain
course paterns also did not differentiate between groups
in our study, although the pattern of pain attacks with pain
between them was relatively more often selected in the
neuropathic pain group than the others; the difference
could not reach statisctically significance. Although PD-Q
is the first instrument using visual paterns for describing
pain types, discriminative features of these patterns may
be especially for the patients with chronic low back pain.
The present data indicate that discriminant capability of
pain course pattern and radiating pain items might be
poor. Despite the differences in development of tools, the
pain descriptors are almost similar in all instruments [24].
Pain evoked by mild pressure and pain evoked by heat or
cold are the differences of PD-Q from other instruments
[24]. On the other hand, the discriminative properties of








Index PPV NPV PLR NLR
0 100 1.2 0.012 0.5 1 1.01 0
1 100 3.7 0.037 0.51 1 1.03 0
2 100 7.5 0.075 0.52 1 1.08 0
3 100 12.5 0.125 0.53 1 1.14 0
4 100 23.7 0.237 0.57 1 1.31 0
5 100 36.2 0.362 0.61 1 1.57 0
6 100 41.2 0.412 0.63 1 1.70 0
7 100 51.2 0.512 0.67 1 2.05 0
8 100 53.7 0.537 0.68 1 2.16 0
9 100 60.0 0.600 0.71 1 2.50 0
10 98.8 67.5 0.663 0.75 0.98 3.04 0.02
11 93.8 67.5 0.613 0.74 0.92 2.89 0.09
12 90.0 67.5 0.575 0.73 0.87 2.77 0.15
13 87.5 71.2 0.587 0.75 0.85 3.04 0.18
14 85.0 75.0 0.600 0.77 0.83 3.4 0.20
15 83.8 76.2 0.600 0.78 0.82 3.52 0.21
16 82.5 77.5 0.600 0.79 0.82 3.67 0.23
17 81.3 80.0 0.613 0.80 0.81 4.06 0.23
18 78.8 81.2 0.600 0.81 0.79 4.19 0.26
19 77.5 82.5 0.600 0.82 0.79 4.43 0.27
20 67.5 86.2 0.537 0.83 0.73 4.89 0.38
21 57.5 90.0 0.475 0.85 0.68 5.75 0.47
22 47.5 93.7 0.512 0.88 0.64 7.53 0.56
23 41.3 96.2 0.375 0.92 0.62 10.87 0.61
24 35.0 96.2 0.312 0.90 0.60 9.21 0.68
25 27.5 97.5 0.250 0.92 0.57 11 0.74
26 26.3 98.7 0.250 0.95 0.57 20.23 0.75
27 23.8 98.7 0.225 0.95 0.56 18.31 0.77
28 20.0 100 0.200 1 0.56 NA 0.80
29 13.8 100 0.138 1 0.53 NA 0.86
30 8.8 100 0.088 1 0.52 NA 0.91
31 6.3 100 0.063 1 0.52 NA 0.93
32 5.0 100 0.050 1 0.51 NA 0.95
33 3.8 100 0.038 1 0.51 NA 0.96
34 2.5 100 0.025 1 0.51 NA 0.97
35 2.5 100 0.025 1 0.51 NA 0.97
36 1.3 100 0.013 1 0.50 NA 0.99
37 1.3 100 0.013 1 0.50 NA 0.99
38 0 100 0 NA 0.5 NA 1
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seven Likert-type items corresponding to the sensory
descriptors were very good like the other studies [15,19].
The LANSS scale and DN4 questionnaire use both inter-
view questions and physical examination and achieve
higher sensitivity and specificity than the screening tools
that use only interview questions [9,12]. The higher diag-
nostic accuracy achieved by the LANSS scale and DN4
questionnaire is hardly surprising given that their scores
also reflect physical tests and emphasizes the importance
of clinical examination [7]. In contrast with DN4 and the
LANSS scale, the PD-Q is a self-administered question-
naire and therefore does not include sensory examination.
PD-Q relies only on interview questions. Despite the dif-
ferences between the DN4, LANSS, and PD-Q mentioned
earlier, it appears that several items are common to these
three questionnaires. Moreover, it is important to note that
higher correlation between the LANSS, DN4 scale, and
PD-Q were obtained in the present study.
In linguistic validation phase, the most difficult topic in
ensuring the compliance is the definition of pain course
paterns during the forward translation process. There
were also minor differences among the translators during







Index PPV NPV PLR NLR
0 100 1.2 0.012 0.70 1 1.01 0
1 100 3.7 0.037 0.71 1 1.03 0
2 100 7.5 0.075 0.72 1 1.08 0
3 100 12.5 0.125 0.73 1 1.14 0
4 100 23.7 0.237 0.75 1 1.31 0
5 100 36.2 0.362 0.79 1 1.57 0
6 99.4 41.2 0.406 0.80 0.97 1.69 0.01
7 98.8 51.2 0.500 0.83 0.95 2.02 0.02
8 98.1 53.7 0.518 0.83 0.92 2.12 0.04
9 97.5 60.0 0.575 0.85 0.91 2.44 0.04
10 95.0 67.5 0.625 0.87 0.85 2.92 0.07
11 90.0 67.5 0.575 0.86 0.74 2.77 0.15
12 84.4 67.5 0.519 0.86 0.65 2.60 0.23
13 81.9 71.2 0.531 0.87 0.63 2.84 0.25
14 79.4 75.0 0.544 0.88 0.61 3.18 0.27
15 76.3 76.2 0.525 0.88 0.58 3.21 0.31
16 75.0 77.5 0.525 0.89 0.57 3.33 0.32
17 73.8 80.0 0.538 0.90 0.57 3.69 0.33
18 71.9 81.2 0.531 0.90 0.55 3.82 0.35
19 70.6 82.5 0.531 0.90 0.55 4.03 0.36
20 61.9 86.2 0.481 0.91 0.49 4.48 0.44
21 52.5 90.0 0.425 0.92 0.45 5.25 0.53
22 41.3 93.7 0.350 0.94 0.41 6.56 0.63
23 34.4 96.2 0.306 0.95 0.39 9.05 0.68
24 27.5 96.2 0.237 0.94 0.36 7.24 0.75
25 20.6 97.5 0.181 0.95 0.34 8.24 0.81
26 17.5 98.7 0.162 0.97 0.34 13.46 0.84
27 14.4 98.7 0.131 0.96 0.33 11.08 0.87
28 12.5 100 0.125 1 0.33 NA 0.87
29 7.5 100 0.075 1 0.32 NA 0.92
30 4.4 100 0.044 1 0.31 NA 0.96
31 3.1 100 0.031 1 0.31 NA 0.97
32 2.5 100 0.025 1 0.31 NA 0.97
33 1.9 100 0.019 1 0.30 NA 0.98
34 1.3 100 0.013 1 0.30 NA 0.99
35 1.3 100 0.013 1 0.30 NA 0.99
36 0.6 100 0.006 1 0.30 NA 0.99
37 0.6 100 0.006 1 0.30 NA 0.99
38 0 100 0 NA 0.30 NA 1
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the forward translation process in Likert-type items 3, 5
and 7 that were amended by expert panel. All PD-Q items,
except pain course patterns and radiating pain, were
answered by all patients, and multiple answers were not
noted for any item, showing that they were well under-
stood. On the basis of patient interviews, the most fre-
quently asked issue during the test period are “how
should I mark the pain intensity questions?” and “how
should I draw the arrow?.” Also when the outcome of all
scores were taken into consideration, it is clear that the
translation procedure was completed successfully. Adap-
tation of the PD-Q will help to prevent the existence of
multiple versions of an instrument in Turkish. In this study,
it was shown that the Turkish version of PD-Q can be used
to discriminate between neuropathic and nociceptive
types of pain in clinical practice when the mixed pain
group is not taken into consideration.
However, this study has some limitations such as diffi-
culty to determine if the outcome of PD-Q influenced
by sociodemographic characteristics of participant
due to small sample size. Moreover, this validation
study was conducted in a single university hospital by
the contributions of two separate departments, but
the strength of representation of the whole Turkish
community could be better if it was a multicenter
study. Moreover, the present study was performed
only in a clinical setting. Although these findings
support the generalizability of the results, the precision of
the test needs to be further evaluated in epidemiologic
studies.
In conclusion, the Turkish version of the PD-Q shows
good psychometric and discriminant properties for
detecting the presence of a neuropathic component in
patients with chronic pain. Further longitudinal studies
with larger samples are needed to test the validation of
this questionnaire for epidemiological purposes and also
to evaluate the sensitivity of PD-Q response to treatment
over time with proper treatment modality.
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